公开(公告)号：KR1019940000012A

公开(公告)日：1994-01-17

申请号：KR1019920009493

申请日：1992-06-01

Applicant: 한국화학연구원

Inventor： 유응걸 ,  김형래 ,  김경만 ,  송종환 ,  정근희 ,  황인택

IPC: A01N43/10

公开(公告)号：KR101891315B1

公开(公告)日：2018-08-24

申请号：KR1020170097574

申请日：2017-08-01

Applicant: 한국화학연구원

Inventor： 박철민 ,  이선경 ,  송종환 ,  장수진 ,  김형준 ,  데이비드셤

IPC: A61K31/47 ,  A61K31/7048 ,  A23L33/10

CPC classification number: A61K31/47 ,  A23L33/10 ,  A23V2002/00 ,  A23V2200/314 ,  A61K31/7048

Abstract: 본발명은퀴놀린 4-온유도체, 이의약학적으로허용가능한염, 또는이를유효성분으로포함하는폐렴의예방또는치료용약학적조성물에관한것이다. 본발명에따른퀴놀린 4-온유도체는우수한항균활성을가질뿐만아니라, 종래일반적으로사용되고있는항균제와는달리약물내성을갖고있는폐렴균에대해서도항균활성이뛰어나므로이들폐렴균에의해서발병되는폐렴의예방또는치료용약학적조성물로써유용하게사용될수 있다.

公开(公告)号：KR101753654B1

公开(公告)日：2017-07-05

申请号：KR1020150146654

申请日：2015-10-21

Applicant: 한국화학연구원

Inventor： 박철민 ,  최상운 ,  이선경 ,  송종환 ,  박지훈 ,  손유화 ,  김광록 ,  김지은

IPC: C07D471/04 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D401/14 ,  A61K31/437 ,  A61K31/497 ,  A23L1/30

Abstract: 본발명은 3-(4-(피페라진-1-일)벤즈아미도)-1H-피라졸로피리딘유도체또는이의약학적으로허용가능한염, 이의제조방법및 이를유효성분으로포함하는 MELK(maternal embryonic leucine zipper kinase) 관련질환의예방또는치료용약학적조성물에관한것이다. 본발명에따른 3-(4-(피페라진-1-일)벤즈아미도)-1H-피라졸로피리딘유도체는 MELK의발현을억제하는효과가우수하므로, 유방암, 폐암, 방광암, 림프종, 다형성신경교아증, 자궁경부암등의암과같은 MELK 관련질환을예방또는치료하는데유용하게사용할수 있다.

公开(公告)号：KR1020150057582A

公开(公告)日：2015-05-28

申请号：KR1020130141105

申请日：2013-11-20

Applicant: 한국화학연구원

Inventor： 김성수 ,  이상달 ,  김광록 ,  김희연 ,  송종환 ,  채종학 ,  김범태 ,  이혁 ,  정주미

IPC: A61K31/4196 ,  A61K8/49 ,  A61P17/14 ,  A61Q7/00

CPC classification number: A61K31/4196 ,  A61K8/49

Abstract: 본발명은트리아졸을유도체를함유하는탈모예방또는발모촉진용조성물및 화장료조성물에관한것으로, 본발명의탈모예방또는발모촉진용조성물및 화장료조성물은피부자극성이없으면서도우수한발모촉진효과를나타내탈모예방또는탈모증치료에매우효과적이다.

Abstract translation: 本发明涉及包含用于预防脱发和促进毛发生长的三唑衍生物的组合物和化妆品组合物。 组合物和化妆品组合物不刺激皮肤，具有促进毛发生长的优异效果，因此对脱发的预防或治疗都是有效的。

公开(公告)号：KR1020140143329A

公开(公告)日：2014-12-16

申请号：KR1020140067225

申请日：2014-06-02

Applicant: 재단법인 의약바이오컨버젼스연구단 ,  한국화학연구원

Inventor： 김성훈 ,  권남훈 ,  김대규 ,  이선경 ,  송종환

IPC: C07D213/36 ,  A61K31/4402 ,  A61P35/00

CPC classification number: C07D413/12 ,  C07C235/76 ,  C07D213/74 ,  C07D213/75 ,  C07D213/89 ,  C07D261/14 ,  C07D285/12 ,  C07D285/135 ,  C07D295/18 ,  C07D295/192 ,  C07D333/20 ,  C07D333/24 ,  C07D333/36 ,  C07D333/38 ,  C07D409/12 ,  C07D213/36 ,  A61K31/4402 ,  C07D213/00 ,  C07D213/02 ,  C07D213/38 ,  C07D213/42

Abstract: The present invention relates to a novel anticancer composition and, more particularly, to a maleic acid derivative compound represented by Chemical Formula 1, a method for preparing the compound, and a pharmaceutical composition comprising the compound. The maleic acid derivative of the present invention selectively inhibits proliferation of a cancer cell line without affecting normal cells by inhibiting AIMP2-DX2 expression. Thus, the pharmaceutical composition containing the maleic acid derivative and a pharmaceutically acceptable salt thereof, as active ingredients, can be used for preventing and treating cancer.

Abstract translation: 本发明涉及一种新的抗癌组合物，更具体地说，涉及由化学式1表示的马来酸衍生物化合物，该化合物的制备方法和包含该化合物的药物组合物。 本发明的马来酸衍生物通过抑制AIMP2-DX2的表达，选择性地抑制癌细胞系的增殖而不影响正常细胞。 因此，含有马来酸衍生物及其可药用盐作为活性成分的药物组合物可用于预防和治疗癌症。

公开(公告)号：KR101246911B1

公开(公告)日：2013-03-25

申请号：KR1020100108201

申请日：2010-11-02

Applicant: 서울대학교산학협력단 ,  한국화학연구원

Inventor： 김성훈 ,  한정민 ,  김형래 ,  전동주 ,  송종환 ,  박경은

IPC: C07D401/12 ,  C07D239/34 ,  A61K31/513 ,  A61P29/00

CPC classification number: C07D239/60 ,  C07D239/52 ,  C07D401/12

Abstract: 본 발명은 신규한 2,4-피리미딘 유도체 및 이의 용도에 관한 것으로, 보다 상세하게는 전신성 홍반성 낭창에 효과가 있는 피리미딘 유도체, 이를 유효성분으로 포함하는 전신성 홍반성 낭창 예방 및 치료용 조성물 및 이를 스크리닝하는 방법에 관한 것이다. 본 발명자들은 gp96의 세포내 거류에 대한 분자 닻(anchor)인 AIMP1의 기능을 모방하여 gp96의 표면 전좌(translocation)를 저해하는 신규 물질을 찾았고, 이들 물질이 in vitro, in vivo상에서 자가면역질환 중 SLE 형질을 완화하여 SLE를 예방 및 치료하는 효과가 있음을 확인하였다. 따라서, 본 발명은 상기 기작을 이용하여 SLE의 치료제를 스크리닝하고, SLE를 예방 또는 치료하는 새로운 방법을 제공한다.

公开(公告)号：KR1020120111886A

公开(公告)日：2012-10-11

申请号：KR1020110114754

申请日：2011-11-04

Applicant: 한국화학연구원

Inventor： 이선경 ,  박철민 ,  송종환 ,  임동철 ,  조우영

IPC: C07D311/22 ,  C07D413/06 ,  A61K31/352 ,  A61P9/00

Abstract: PURPOSE: A pharmaceutical composition containing novel chromeme derivative, pharmaceutically acceptable salts or isomers thereof is provided to prevent or treat blood clot-related diseases or cancer. CONSTITUTION: A chromene derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating PAR-1 activation-related diseases contains the chromene derivative, pharmaceutically acceptable salt, isomer as an active ingredient. A pharmaceutical composition for cardiovascular disease treatment aid contains the chromene derivative, pharmaceutically acceptable salt, or isomer as an active ingredient. A PAR-1 antagonist contains the chromene derivative, pharmaceutically acceptable salt, or isomer as an active ingredient.

Abstract translation: 目的：提供含有新的chromeme衍生物，其药学上可接受的盐或异构体的药物组合物，用于预防或治疗血块相关疾病或癌症。 构成：色烯衍生物由化学式1表示。用于预防或治疗PAR-1活化相关疾病的药物组合物含有色烯衍生物，药学上可接受的盐，异构体作为活性成分。 用于心血管疾病治疗助剂的药物组合物含有色烯衍生物，药学上可接受的盐或异构体作为活性成分。 PAR-1拮抗剂含有色烯衍生物，药学上可接受的盐或异构体作为活性成分。

公开(公告)号：KR1020090005842A

公开(公告)日：2009-01-14

申请号：KR1020070069210

申请日：2007-07-10

Applicant: 한국화학연구원

Inventor： 전동주 ,  노재성 ,  송종환 ,  이계형 ,  김익연 ,  김순기 ,  강남숙 ,  천혜경 ,  조영식 ,  송진숙 ,  민용기 ,  김성환

IPC: C07D231/04 ,  A61K31/415 ,  A61P19/04

Abstract: A novel carbonitrile compound or its pharmaceutically acceptable salt, a method for preparing the compound, and a pharmaceutical composition containing compound are provided to prevent and treat osteoarthritis and various cancer without side effect. A carbonitrile compound is represented by the formula 1, wherein n is 1 or 2; R1 is H, halogen-substituted or unsubstituted linear or branched saturated or unsaturated C1-C10 alkyl, C3-C7 cycloalkyl, C1-C10 alkoxy, C1-C10 alkylthio, hydroxy-C1-C10 alkyl, C1-C10 alkylcarbonyl, C1-C10 alkylthio-C1-C10 alkyl, C3-C7 cycloalkyl-C1-C10 alkyl, C3-C7 cycloalkyl-C1-C10 alkyl, C1-C10 alkoxy-C1-C10 alkyl, phenyl, ar-C1-C10 alkyl, or ar-C1-C10 alkoxy group; and R2 linear or branched saturated or unsaturated C1-C10 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C10 alkyl, phenyl, ar-C1-C10 alkyl, C1-C10 alkoxycarbonyl, or ar-C1-C10 alkoxycarbonyl group.

Abstract translation: 提供新的腈化合物或其药学上可接受的盐，制备该化合物的方法和含有药物组合物的化合物以预防和治疗骨关节炎和各种癌症而没有副作用。 腈化合物由式1表示，其中n为1或2; R1是H，卤素取代或未取代的直链或支链饱和或不饱和C 1 -C 10烷基，C 3 -C 7环烷基，C 1 -C 10烷氧基，C 1 -C 10烷硫基，羟基-C 1 -C 10烷基，C 1 -C 10烷基羰基，C 1 -C 10 烷硫基-C 1 -C 10烷基，C 3 -C 7环烷基-C 1 -C 10烷基，C 3 -C 7环烷基-C 1 -C 10烷基，C 1 -C 10烷氧基-C 1 -C 10烷基，苯基，芳基-C 1 -C 10烷基或芳烷基 -C 10烷氧基 和R 2直链或支链饱和或不饱和的C 1 -C 10烷基，C 3 -C 7环烷基，C 3 -C 7环烷基-C 1 -C 10烷基，苯基，芳基-C 1 -C 10烷基，C 1 -C 10烷氧基羰基或芳基-C 1 -C 10烷氧基羰基 。

公开(公告)号：KR100877394B1

公开(公告)日：2009-01-07

申请号：KR1020070069467

申请日：2007-07-11

Applicant: 한국화학연구원

Inventor： 이계형 ,  전동주 ,  김익연 ,  송종환

IPC: A61K31/415 ,  A61P19/10

CPC classification number: A61K31/415 ,  A61K31/121 ,  A61K31/50

Abstract: A pharmaceutical composition for treating and preventing osteoporosis is provided to improve the selectivity and inhibitory activity to cathepsin K. A pharmaceutical composition for treating and preventing osteoporosis comprises a carbonitrile compound represented by the formula 1, wherein n is 1 or 2; R1 is H, F-substituted or unsubstituted linear or branched saturated or unsaturated C1-C10 alkyl, C3-C7 cycloalkyl, C1-C10 alkoxy, C1-C10 alkylthio, C1-C10 hydroxyalkyl, C1-C10 alkylcarbonyl, C1-C10 alkylthio C1-C10 alkyl, C3-C7 cycloalkyl C1-C10 alkyl, C3-C7 cycloalkyl C1-C10 alkoxy, C1-C10 alkoxy C1-C10 alkyl, phenyl, ar-C1-C10 alkyl, or ar-C1-C10 alkoxy group; and R2 is linear or branched saturated or unsaturated C1-C10 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl C1-C10 alkyl, phenyl, ar-C1-C10 alkyl, C1-C10 alkoxycarbonyl, or ar-C1-C10 alkoxy group.

Abstract translation: 提供了用于治疗和预防骨质疏松症的药物组合物，以提高对组织蛋白酶K的选择性和抑制活性。用于治疗和预防骨质疏松症的药物组合物包括由式1表示的腈化合物，其中n为1或2; R1是H，F-取代或未取代的直链或支链饱和或不饱和的C1-C10烷基，C3-C7环烷基，C1-C10烷氧基，C1-C10烷硫基，C1-C10羟基烷基，C1-C10烷基羰基，C1-C10烷硫基C1 -C 10烷基，C 3 -C 7环烷基C 1 -C 10烷基，C 3 -C 7环烷基C 1 -C 10烷氧基，C 1 -C 10烷氧基C 1 -C 10烷基，苯基，芳基-C 1 -C 10烷基或芳烷基-C 1 -C 10烷氧基; 并且R 2是直链或支链饱和或不饱和的C 1 -C 10烷基，C 3 -C 7环烷基，C 3 -C 7环烷基C 1 -C 10烷基，苯基，芳基-C 1 -C 10烷基，C 1 -C 10烷氧基羰基或芳烷基-C 1 -C 10烷氧基 。

公开(公告)号：KR100833799B1

公开(公告)日：2008-05-30

申请号：KR1020070002725

申请日：2007-01-10

Applicant: 한국화학연구원

Inventor： 전동주 ,  노재성 ,  송종환 ,  이계형 ,  김익연 ,  박창민 ,  소원영 ,  이지선 ,  김은주 ,  강남숙 ,  천혜경 ,  조영식 ,  송진숙 ,  배명애 ,  김지현 ,  조중명 ,  노성구 ,  현영란 ,  이철순 ,  이재일 ,  유성은

IPC: C07D401/06 ,  C07D413/14

Abstract: 1-[1-(3,4-Dialkoxyaryl)-pyridylmethyl]-1H-pyrazole compounds are provided to inhibit activity of PDE-4(phosphodiesterase-4) with high activity and selectivity without side effects, so that the compounds are useful for treating inflammation diseases, neurodegenerative disease and cancers. 1-[1-(3,4-Dialkoxyaryl)-pyridylmethyl]-1H-pyrazole compounds represented by the formula(1) are provided, wherein A is N or CH; R1 is linear or branched, saturated or unsaturated (C1-C7)alkyl or halogen-substituted linear or branched, saturated or unsaturated (C1-C7)alkyl; R2 is hydrogen atom, (C3-C7)cycloalkyl or (C3-C8)cycloalkylmethyl; R3, R4 and R5 are each independently hydrogen atom, phenyl, pyridinyl, N-oxypyridinyl, linear or branched, saturated or unsaturated (C1-C7)alkyl, (C3-C7)cycloalkyl, (C3-C10)cycloalkyl(C1-C7)alkyl, halogen atom, cyano, nitro, amino, mono- or di(C1-C7)alkylamino, mono- or di(C1-C7)alkylaminocarbonyl, (C3-C7)cycloalkylamino, 3- to 7-membered saturated or unsaturated hetero ring containing oxygen, nitrogen or sulfur in hetero ring, guanidinyl, ureido, benzyl, benzyloxy, formyl, (C1-C7)alkanoyl, (C1-C7)alkoxy, (C1-C7)alkoxy(C1-C7)alkyl, hydroxy(C1-C7)alkyl, carboxyl or (C1-C7)alkoxycarbonyl; and R6 is pyridinyl or N-oxypyridinyl group.

Abstract translation: 提供1- [1-（3,4-二烷氧基芳基） - 吡啶基甲基] -1H-吡唑化合物以抑制具有高活性和选择性的PDE-4（磷酸二酯酶-4）的活性而没有副作用，使得该化合物可用于 治疗炎症疾病，神经退行性疾病和癌症。 提供由式（1）表示的1- [1-（3,4-二烷氧基芳基） - 吡啶基甲基] -1H-吡唑化合物，其中A是N或CH; R1是直链或支链饱和或不饱和（C1-C7）烷基或卤素取代的直链或支链饱和或不饱和（C1-C7）烷基; R2是氢原子，（C3-C7）环烷基或（C3-C8）环烷基甲基; R 3，R 4和R 5各自独立地为氢原子，苯基，吡啶基，N-氧代吡啶基，直链或支链，饱和或不饱和的（C1-C7）烷基，（C3-C7）环烷基，（C3-C10）环烷基 ）（C 1 -C 7）烷基氨基羰基，（C 3 -C 7）环烷基氨基，3至7元饱和或不饱和的（C 1 -C 7）烷基氨基， 杂环中含氧，氮或硫的杂环，胍基，脲基，苄基，苄氧基，甲酰基，（C1-C7）烷酰基，（C1-C7）烷氧基，（C1-C7）烷氧基（C1-C7） （C 1 -C 7）烷基，羧基或（C 1 -C 7）烷氧基羰基; R6是吡啶基或N-氧代吡啶基。